Virpax Pharmaceuticals Files Provisional Patent Application For NSAID Formulation And Method
Portfolio Pulse from Happy Mohamed
Virpax Pharmaceuticals has filed a provisional patent application for its Epoladerm product, an over-the-counter diclofenac topical spray film for pain associated with Osteoarthritis. The company has completed its IND enabling trials for Epoladerm and expects the patent to expand protection and increase the patent life for this formulation.
August 10, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Virpax's new patent application for Epoladerm could strengthen its intellectual property rights and potentially extend the product's market exclusivity, which may positively impact the company's future revenues.
Patents provide companies with exclusive rights to manufacture and sell their products, preventing competitors from entering the market. If granted, this patent could extend the market exclusivity of Epoladerm, potentially leading to increased sales and revenues for Virpax.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100